The collection of intraperitoneal fluid in a patient with known intraabdominal cancer is generally caused by intraperitoneal spread of disease, and, if malignant cells are identified in the peritoneal fluid, is called malignant ascites. 1 Approximately 6 percent of patients admitted to hospice will have malignant ascites. 2 Certain cancers are prone to causing intra-abdominal fluid accumulation. Thirty percent of patients with ovarian cancer have ascites at diagnosis and over 60 percent at the time of death. Other cancers that result in malignant ascites include those of the endometrium, breast, colon, stomach, pancreas, and lung, which account for nearly 80 percent of all cases of malignant ascites. Less common causes include mesothelioma, non-Hodgkins lymphoma, prostatic carcinoma, multiple myeloma, and melanoma.
Malignant ascites is classified into four relatively distinct categories:
1. Peripheral: This is the most common type and accounts for 50 percent of the cases. Deposits of tumor cells are found on the surface of the parietal or visceral peritoneum. The formation of peripheral ascites is largely the result of mechanical interference with venous or lymphatic drainage at the level of the peritoneal space. Increased capillary permeability also contributes to ascites formation.
Central:
In this type, the tumor invades the liver, resulting in compression of the portal venous or lymphatic systems. The ascites that occurs is similar to that formed as a result of primary liver disease, that is, elevated hydrostatic pressure, combined with decreased oncotic pressure. However, in central malignant ascites, the decreased oncotic pressure is more the result of limited protein intake and catabolic state associated with cancer rather than impaired liver protein synthesis. Fifteen percent of the cases of malignant ascites are the central type.
Mixed:
In these cases, tumor is present both in the liver and on the peritoneal surfaces. In this type of ascites, which occurs in 15 percent of all cases, fluid accumulation is the effect of the combined peripheral and central pathophysiological processes.
Chylous:
In this uncommon type of malignant ascites, tumor infiltration of the retroperitoneal space causes obstruction of lymphatic flow through the lymph nodes. Leakage from the lymphatic channels as a direct result of tumor invasion may also occur. 2, 3 Not all ascites in patients with cancer is the result of malignancy. Underlying advanced liver disease with portal hypertension, portal venous thrombosis, congestive heart failure, nephrotic syndrome, pancreatitis, hepatic venous obstruction, and bowel perforation should be considered. 3 The median survival of patients with symptomatic malignant ascites is approximately two months, and therefore management should be judicious and might include the following approaches:
Medical therapy: Loop diuretics, salt restriction, and aldosterone-inhibiting diuretics are generally not helpful, since sodium retention is not a cause of the ascites. However, patients with portal hypertension related ascites caused by massive liver metastases (central type) may experience some palliation when treated with diuretics. 1 Paracentesis: Repeated paracentesis may be necessary to provide symptomatic improvement. The removal of up to five liters per day until the abdomen is "dry" is generally well tolerated by patients, especially those with peripheral edema because this peripheral reserve of fluid is used for rapid restoration of effective circulating volume. 3 However, this approach may heighten the risk of infection, electroyte and fluid imbalance, and cause intraperitoneal visceral injury. 1 Peritoneovenous shunting: Although the concept of returning ascitic fluid to the intravascular space is not new, recent improvements in technology with peritoneovenous devices (LeVeen or Denver shunt) have led to their use. These devices consist of a length of multiply perforated tube inserted in the peritoneal cavity, a length of tubing placed into the superior vena cava or the right atrium, and a unidirectional flow valve connecting the two arms. The main difference between the LeVeen and Denver shunts is the one-way valve in the Denver shunt that can be manually pumped to flush any accumulated debris at periodic intervals. 4 In this issue of the Journal, Iyengar and Herzog 5 report on the successful use of the Pleurx catheter for external drainage of ascitic fluid in three patients with malignant ascites due to recurrent ovarian carcinoma. The advantage of this system is that repeated paracentesis is unnecessary, placement is less complicated, and home management of fluid reaccumulation is possible. Combining the studies cited by Iyengar and Herzog 5 as well as their data, the average survival in patients with malignant ascites managed by the Pleurx catheter was 70 days, which is comparable to the use of a peritoneovenous shunt.
Surgical intervention: This approach has met with limited success and has the significant potential to interfere with quality of life.
Radioactive isotopes: Although promising, more studies are necessary for this approach to be appropriate for hospice patients.
